A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer

Liver Cancer Clinical Trial

Official title:

A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04309747
• Other study ID #: nanosecond001
• Secondary ID: nanosecond knife
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 1, 2020
• Est. completion date: December 1, 2022

Study information

• Verified date: March 2020
• Source: First Affiliated Hospital of Zhejiang University
• Contact: Tian'an Jiang, PhD
• Phone: 18857127666
• Email: tiananjiang[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.

Description:

The prospective, multi-center, single-arm clinical trial is to evaluate whether the nanosecond knife can achieve the effectiveness and safety of liver cancer ablation treatment. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. This clinical trial requires 190 subjects. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary outcome (the effective rate of nanosecond knife ablation for liver cancer) and secondary outcomes (partial response rate, secondary ablation rate, progression-free survival, overall survival rate, quality of life score, alpha-fetoprotein levels, technical success rate, local control rate, complication rate, device Use satisfaction of nanosecond knife ablation for liver cancer). The first 2-month follow-up after the operation, CT, MR, CEUS, liver function, tumor markers were reviewed monthly to observe the lesion necrosis and tumor marker changes. After that, tumor markers, CEUS, or three-phase CT/MRI of liver were examined every 2 to 3 months. After two years, tumor markers, CEUS, or three-phase CT/MRI of liver were examined every 3 to 6 months. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 190
• Est. completion date: December 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Liver malignant tumors with clear histopathology and cytology, or liver malignant tumors that meet clinical diagnosis and staging criteria.

2. Age: 18-75 years old, regardless of gender.

3. Liver function: Child-Pugh A or B, or Child C will reach B.

4. No serious heart, lung, brain and other organ dysfunction. Normal or nearly normal blood coagulation function. Prothrombin time does not exceed 50% of the normal control, and platelets are more than 50 × 109 / L.

5. It is usually suitable for single tumor with a maximum diameter of =5cm, or the number of tumors of =3 and a maximum diameter of =3cm.

6. For single tumors > 5 cm in diameter that cannot be surgically removed, or multiple tumors with a maximum diameter > 3 cm, local ablation can be used as p palliative comprehensive treatment.

7. According to CT and MRI, there are no macrovascular and bile duct invasions visible by the naked eye.

8. Patients signed informed consent to participate in the trial.

Exclusion Criteria:

1. The lesion of liver cancer is huge or diffuse ;

2. Merged portal vein to secondary branch tumor thrombus or hepatic vein tumor thrombus, invasion of nearby organs or distant metastasis;

3. tumors located on the surface of the liver, of which more than 1/3 tumor size are bare;

4. liver function: Child-pugh C, those could not improve after liver protective treatment;

5. Esophageal (bottom of stomach) varices rupture and bleeding within 1 month before treatment;

6. Uncorrectable coagulation dysfunction and severe haematological abnormalities, who tend to severe bleeding;

7. Refractory large amount of ascites and cachexia;

8. active infection, especially inflammation of the biliary system;

9. Severe failure of major organs such as liver, kidney, heart, lung and brain;

10. Patients with unconsciousness or unable to cooperate with treatment;

11. Subjects could not be followed up and fell off;

12. Those who discontinued treatment, or the case records were incomplete for various reasons, and were determined by researchers to be unable to be evaluated.

Related Conditions & MeSH terms

• Liver Cancer
• Liver Neoplasms

Intervention

Procedure:
• nanosecond knife liver cancer ablation
This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
First Affiliated Hospital of Zhejiang University	First Affiliated Hospital of Xinjiang Medical University, Shulan (Hangzhou) Hospital, The First Affiliated Hospital of Zhengzhou University

References & Publications (6)

Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation. Radiology. 2010 Apr;255(1):289-300. doi: 10.1148/radiol.09090927. — View Citation

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30. — View Citation

Distelmaier M, Barabasch A, Heil P, Kraemer NA, Isfort P, Keil S, Kuhl CK, Bruners P. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins. Radiology. 2017 Dec;285(3):1023-1031. doi: 10.1148/radiol.2017161561. Epub 2017 Aug 11. — View Citation

Frühling P, Nilsson A, Duraj F, Haglund U, Norén A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol. 2017 Apr;43(4):751-757. doi: 10.1016/j.ejso.2016.12.004. Epub 2017 Jan 11. — View Citation

Gu YK, Luo RG, Huang JH, Si Tu QJ, Li XX, Gao F. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol. 2010 Dec 7;16(45):5766-72. — View Citation

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness analysis	The effective rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	partial response rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	secondary ablation rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	progression-free survival of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	overall survival rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	quality of life score of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	alpha-fetoprotein levels	12 months
Secondary	Secondary validity analysis	technical success rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	local control rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	complication rate of nanosecond knife ablation for liver cancer	12 months
Secondary	Secondary validity analysis	device Use satisfaction of nanosecond knife ablation for liver cancer	12 months